BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Oct 04, 2010
 |  BioCentury  |  Politics, Policy & Law

Commentary: Passing the Avandia test

FDA passed an important test on Avandia; Congress should follow suit

BioCentury published a Commentary in March criticizing FDA leadership for its long silence in the face of political bullying on Avandia rosiglitazone. We argued FDA had an obligation to respond to allegations from members of Congress that the agency's allegedly "cozy" relationship with Avandia's manufacturer, GlaxoSmithKline plc, had led it to look the other way while the drug "caused approximately 83,000 excess heart attacks between 1999 and 2007."

BioCentury added that FDA was at a critical inflection point: The way it handled Avandia would determine whether a culture of selective, misleading leaks to Congress, alarmist media coverage and grandstanding politicians would supersede scientific decision-making (see BioCentury, March 8).

Attacks on the integrity of the agency's staff, especially charges that they put company profits ahead of the lives of American patients, had to be answered: A failure to respond would suggest the accusations were true.

Our point was not to argue for a specific...

Read the full 760 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >